Is Latanoprost + Netarsudil registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 1 valid registration of Latanoprost + Netarsudil, including ROCLANDA (50,200 µ/ml,µ/ml, Eye drops, solution, SAR 48.00).

Is Latanoprost + Netarsudil approved by the US FDA?

Drugs@FDA lists 1 application product line for Latanoprost + Netarsudil, including ROCKLATAN (Prescription).

Is Latanoprost + Netarsudil authorised in the European Union?

EMA lists 1 centrally authorised medicine containing Latanoprost + Netarsudil: Roclanda.

Active substances

Latanoprost + Netarsudil

SFDA 1
US FDA 1
EMA 1
US price lines 1
NHS prices 1

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
ROCLANDA	50,200 µ/ml,µ/ml	Eye drops, solution · Ocular use	1 Bottle	SAR 48.00	NCE · Prescription	Santen Oy	Valid

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
ROCKLATAN	0.005%;EQ 0.02% BASE	solution/drops · ophthalmic	ALCON LABS INC	Prescription	12 Mar 2019

EMA European Union — centrally authorised medicines

Roclanda Santen Oy · Authorised · authorised 7 Jan 2021 · ATC S01EE

Therapeutic indication (EMA)

Roclanda is indicated for the reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction.

Prices — United States and England

Source	Product as listed	Price	Unit / pack	Date
US NADAC	ROCKLATAN 0.02%-0.005% EYE DRP	$139.40317	per ML	23 Sep 2026
NHS Drug Tariff	Latanoprost 50micrograms/ml / Netarsudil 200micrograms/ml eye drops	£10.00	2.5 ml	1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Components

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.